Summit Therapeutics Inc.
SMMT
Classificação em ações
#1701
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Preço da ação
$15.32
Valor de mercado
$12.22B
Variação (1 dia)
-3.25%
Variação (1 ano)
-20.07%
País
US
Negociar Summit Therapeutics Inc. (SMMT)
Categoria
Healthcare
Histórico de preços das ações de Summit Therapeutics Inc. (SMMT)
Preço de fecho mais alto: $16.33 em 2026-10-01
Preço de fecho mais baixo: $11.32 em 2015-03-01
Preço de fecho mais baixo: $11.32 em 2015-03-01
Histórico de preços das ações da Summit Therapeutics Inc. de 2015 a 2026
Desempenho anual do preço das ações
| Ano | Desempenho |
|---|---|
| 2026 (TTM) | -6.38% |
| 2025 | -2.36% |
| 2024 | 648.94% |
| 2023 | -27.28% |
| 2022 | -16.52% |
| 2021 | -23.50% |
| 2020 | 244.19% |
| 2019 | 23.13% |
| 2018 | -88.74% |
| 2017 | 19.67% |
| 2016 | -15.67% |
| 2015 | 0.00% |
Preço das ações de empresas similares ou concorrentes
| Empresa | Preço da ação | Variação 1a% | País |
|---|---|---|---|
| $533.96 | 25.21% |
US
|
|
| $232.80 | 767.04% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $882.27 | 8.36% |
NL
|
|
| $289.74 | 1.80% |
BE
|
